HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
ImmunityBio Inc
ImmunityBio Inc IBRX | 0.00 |
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:
IBRX) with a Buy and maintains $15 price target.
